A Plasma eMTBR-Tau Immunoassay for Detection of Advanced Insoluble Tau Pathology
A new plasma immunoassay measuring eMTBR-tau detects advanced insoluble tau pathology in Alzheimer's disease with accuracy comparable to mass spectrometry across four cohorts.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Researchers have developed a plasma immunoassay for endogenously cleaved microtubule-binding region tau (eMTBR-tau) that identifies advanced tau pathology in Alzheimer's disease, according to a study published in JAMA. The assay was validated across four independent cohorts and produced results comparable to those obtained with mass spectrometry, the current reference standard for measuring tau species in biofluids. The test targets a specific tau fragment containing residue 243 that originates from the microtubule-binding region of the protein, which becomes exposed when tau aggregates into insoluble filaments characteristic of advanced Alzheimer's pathology.
The same JAMA publication reports that fluid eMTBR-tau containing residue 243 may also serve as a potential diagnostic biomarker for late-stage chronic traumatic encephalopathy (CTE) and symptomatic frontotemporal lobar degeneration, based on a case-control study included in the research. This suggests the biomarker could have utility across multiple neurodegenerative conditions characterized by tau aggregation.
Separately, a cohort study published in JAMA Neurology found that blood levels of phosphorylated tau 217 (p-tau217) in cognitively unimpaired individuals were linked with 5- and 10-year risks of developing mild cognitive impairment and dementia. This reinforces the growing evidence that blood-based tau biomarkers can track disease progression years before symptom onset. Meanwhile, a systematic review and meta-analysis in Alzheimer's Research & Therapy reported that people with type 2 diabetes had a 53% higher risk of Alzheimer's disease, highlighting a significant metabolic risk factor for the condition.
Other recent neuroscience findings include reduced cerebrospinal fluid waves during sleep in older adults, which may impair brain debris clearance, and EEG data showing sleep-like slow waves during wakefulness in Parkinson's disease patients correlating with hallucinations and cognitive impairment. A study of over 2,000 MRIs revealed that highly connected neural hubs are particularly vulnerable to atrophy in multiple sclerosis. In autism research, functional MRI data showed greater variability in encoding patterns across nearly all brain networks when autistic adults watched videos compared to neurotypical controls. The BRAIN Initiative has also produced a shared basal ganglia reference atlas mapping millions of cells across non-human primate, marmoset, and mouse brains. In a separate development, Cell Reports retracted a 2025 study on Parkinson's disease models from Denali Therapeutics scientists due to data manipulation.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 2h ago.
Quick answers
What is eMTBR-tau and what does the new plasma test measure?
eMTBR-tau stands for endogenously cleaved microtubule-binding region tau. The plasma immunoassay measures a specific tau fragment containing residue 243 that becomes exposed when tau aggregates into insoluble filaments in advanced Alzheimer's pathology.
How accurate is the new eMTBR-tau plasma test compared to existing methods?
The assay was validated across four independent cohorts and produced results comparable to those obtained with mass spectrometry, the current reference standard for measuring tau species in biofluids.
Can this biomarker detect conditions other than Alzheimer's disease?
The same JAMA publication reports that fluid eMTBR-tau containing residue 243 may also serve as a potential diagnostic biomarker for late-stage chronic traumatic encephalopathy (CTE) and symptomatic frontotemporal lobar degeneration, based on a case-control study.
Coverage (8)
- Why Early Detection Matters, and Why It Is Not Screening Physicians Weekly · 1d ago
- Watch live: The Promise of Early Intervention The Hill · 1d ago
- Blood Test Predicts Dementia; Diabetes and Alzheimer's; Parkinson's Data Retracted MedPage Today · 1d ago
- New Blood Test Could Make Measuring Advanced Alzheimer’s Disease More Accessible Inside Precision Medicine · 1d ago
- Opinion: Alzheimer's won't wait. Neither should we CT Insider · 1d ago
- Blood biomarker helps estimate a person's future risk of cognitive impairment News-Medical · 1d ago
- Tested Positive For Alzheimer's? You May Never Get Sick Forbes · 1d ago
- A Plasma eMTBR-Tau Immunoassay for Detection of Advanced Insoluble Tau Pathology JAMA · 1d ago
Topics
Related trends
The first pill to slow Alzheimer’s could come from an unexpected place
An experimental oral Alzheimer's drug derived from an unexpected medical category shows varied results in phase 3 clinical trials.
The Largest Alzheimer's Genetics Study Yet Found 48 New Links. The Most Promising Clue Isn't About Memory
The largest Alzheimer's genetics study yet has uncovered 48 new links, highlighting how genetics and sleep interact.
David Cameron on Living With Brexit and Ending Alzheimer’s
Former UK Prime Minister David Cameron reveals his mother begged to die from dementia while urging billions in NHS Alzheimer's funding and 18-week diagnosis targets.
Stronger flu shot linked to nearly 55% lower Alzheimer's risk
New research covering nearly 200,000 adults links high-dose influenza vaccination to a 55% reduction in Alzheimer's disease risk, sparking debate over correlation versus causation.
Some people are resistant to dementia
Some people are resistant to dementia, sparking new research
New culprit in early Alzheimer’s: Blood–brain barrier blocks protective proteins
Researchers found that in a mouse model of early-stage Alzheimer's, the blood-brain barrier stopped importing protective proteins before it began to break down.